ADARx Pharmaceuticals, Inc. ADRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.76M | -22.67M | -19.72M | -19.72M | -18.09M |
| Total Depreciation and Amortization | 735.00K | 720.00K | 593.50K | 593.50K | 626.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.43M | 626.00K | 1.08M | 1.08M | 378.00K |
| Change in Net Operating Assets | -3.59M | -1.36M | -1.18M | -1.18M | 330.53M |
| Cash from Operations | -27.19M | -22.68M | -19.23M | -19.23M | 313.44M |
| Capital Expenditure | -367.00K | -77.00K | -723.00K | -723.00K | -992.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 22.13M | 20.04M | 20.37M | 20.37M | -262.17M |
| Cash from Investing | 21.76M | 19.96M | 19.65M | 19.65M | -263.17M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 6.00K | 2.00K | 7.00K | 7.00K | 83.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.00K | 2.00K | 7.00K | 7.00K | 83.00K |
| Foreign Exchange rate Adjustments | 47.00K | 61.00K | 5.50K | 5.50K | 18.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.37M | -2.66M | 436.00K | 436.00K | 50.38M |